Sanofi ex­pects Zan­tac ar­bi­tra­tion case with Boehringer In­gel­heim to be re­solved ear­ly this year

Af­ter years of Zan­tac heart­burn med­ica­tion le­gal ac­tion, French phar­ma Sanofi is see­ing a res­o­lu­tion to at least some of the lit­i­ga­tion.

In Q4 guid­ance re­leased Wednes­day, Sanofi said it ex­pects the oblig­a­tions and in­dem­ni­fi­ca­tion rights be­ing dis­put­ed through ar­bi­tra­tion with Boehringer In­gel­heim will be re­solved this year, with ear­li­est at the end of Q1. Sanofi bought Zan­tac from Boehringer in 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER